Stock Track | Precigen Soars 8.67% in Pre-market on Strong Q1 Results and PAPZIMEOS Launch Success

Stock Track05-14

Precigen's stock surged 8.67% in pre-market trading, driven by investor enthusiasm following the company's release of its first-quarter 2026 financial results after the previous market close.

The biopharmaceutical company reported revenue of $23.25 million, significantly beating analyst estimates of $20.80 million. This represents a dramatic year-over-year increase of over 1,600%, primarily driven by $21.6 million in sales from its newly launched product PAPZIMEOS, which received FDA approval in August 2025.

Precigen also reported a sharply narrowed net loss of $7.93 million compared to $54.2 million a year earlier. Management indicated that current cash reserves combined with anticipated PAPZIMEOS revenue should fund operations to cash flow break-even by the end of 2026, providing positive forward guidance to investors. Analyst sentiment remains bullish with a median price target of $9.50, representing significant upside potential from recent closing levels.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196097824?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-14 16:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196097824","market":"sg","top_or_hot":-1,"title":"Stock Track | Precigen Soars 8.67% in Pre-market on Strong Q1 Results and PAPZIMEOS Launch Success","media":"Stock Track","content":"<p>Precigen's stock surged 8.67% in pre-market trading, driven by investor enthusiasm following the company's release of its first-quarter 2026 financial results after the previous market close.</p><p>The biopharmaceutical company reported revenue of $23.25 million, significantly beating analyst estimates of $20.80 million. This represents a dramatic year-over-year increase of over 1,600%, primarily driven by $21.6 million in sales from its newly launched product PAPZIMEOS, which received FDA approval in August 2025.</p><p>Precigen also reported a sharply narrowed net loss of $7.93 million compared to $54.2 million a year earlier. Management indicated that current cash reserves combined with anticipated PAPZIMEOS revenue should fund operations to cash flow break-even by the end of 2026, providing positive forward guidance to investors. Analyst sentiment remains bullish with a median price target of $9.50, representing significant upside potential from recent closing levels.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Precigen Soars 8.67% in Pre-market on Strong Q1 Results and PAPZIMEOS Launch Success</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Precigen Soars 8.67% in Pre-market on Strong Q1 Results and PAPZIMEOS Launch Success\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-14 16:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Precigen's stock surged 8.67% in pre-market trading, driven by investor enthusiasm following the company's release of its first-quarter 2026 financial results after the previous market close.</p><p>The biopharmaceutical company reported revenue of $23.25 million, significantly beating analyst estimates of $20.80 million. This represents a dramatic year-over-year increase of over 1,600%, primarily driven by $21.6 million in sales from its newly launched product PAPZIMEOS, which received FDA approval in August 2025.</p><p>Precigen also reported a sharply narrowed net loss of $7.93 million compared to $54.2 million a year earlier. Management indicated that current cash reserves combined with anticipated PAPZIMEOS revenue should fund operations to cash flow break-even by the end of 2026, providing positive forward guidance to investors. Analyst sentiment remains bullish with a median price target of $9.50, representing significant upside potential from recent closing levels.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PGEN","symbol_name":"Precigen","start_time":0,"source_url":"","article_id":"1196097824","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196097824","pubTimestamp":1778746718,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Precigen's stock surged 8.67% in pre-market trading, driven by investor enthusiasm following the company's release of its first-quarter 2026 financial results after the previous market close.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PGEN":"Precigen"},"translate_title":"个股追踪|Precigen盘前大涨8.67%，Q1业绩强劲，PAPZIMEOS上市成功","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PGEN":1},"content_text":"Precigen's stock surged 8.67% in pre-market trading, driven by investor enthusiasm following the company's release of its first-quarter 2026 financial results after the previous market close.The biopharmaceutical company reported revenue of $23.25 million, significantly beating analyst estimates of $20.80 million. This represents a dramatic year-over-year increase of over 1,600%, primarily driven by $21.6 million in sales from its newly launched product PAPZIMEOS, which received FDA approval in August 2025.Precigen also reported a sharply narrowed net loss of $7.93 million compared to $54.2 million a year earlier. Management indicated that current cash reserves combined with anticipated PAPZIMEOS revenue should fund operations to cash flow break-even by the end of 2026, providing positive forward guidance to investors. Analyst sentiment remains bullish with a median price target of $9.50, representing significant upside potential from recent closing levels.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196097824","isCrawlerRequest":true}